<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02739711</url>
  </required_header>
  <id_info>
    <org_study_id>AZ 15-259</org_study_id>
    <nct_id>NCT02739711</nct_id>
  </id_info>
  <brief_title>Glycoprotein IIb/IIIa Inhibitors Versus Standard Therapy in Patients With Myocardial Infarction and No-reflow</brief_title>
  <acronym>REVERSE-FLOW</acronym>
  <official_title>Prospective RandomizEd Study Comparing Glycoprotein IIb/IIIa Inhibitors VERsus Standard Therapy in patientS With Myocardial Infarction and Angiographic Evidence of No-reFLOW</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Luebeck</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Luebeck</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim of the study is to examine the effects of glycoprotein IIb/IIIa inhibitors on reperfusion&#xD;
      success assessed by cardiac magnetic resonance imaging in patients with myocardial infarction&#xD;
      and angiographic evidence of no-reflow.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">July 2016</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Infarct size assessed by cardiac magnetic resonance imaging</measure>
    <time_frame>Day 1-10 after myocardial infarction</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Acute Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Glycoprotein IIb/IIIa inhibitor</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Glycoprotein IIb/IIIa inhibitor administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard therapy</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No glycoprotein IIb/IIIa inhibitors</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glycoprotein IIb/IIIa inhibitors</intervention_name>
    <description>Glycoprotein IIb/IIIa inhibitors intravenous bolus followed by an intravenous infusion for 12/18 h plus medical standard therapy</description>
    <arm_group_label>Glycoprotein IIb/IIIa inhibitor</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ST-elevation myocardial infarction and non-ST-elevation myocardial infarction &lt;48 h&#xD;
             after symptom onset&#xD;
&#xD;
          -  Angiographic evidence of no-reflow (Thrombolysis in Myocardial Infarction-flow grade&#xD;
             ≤2) after primary percutaneous coronary intervention&#xD;
&#xD;
          -  Age ≥18 years&#xD;
&#xD;
          -  Informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  ST-elevation myocardial infarction and non-ST-elevation myocardial infarction patients&#xD;
             with Thrombolysis in Myocardial Infarction-flow 3 after primary percutaneous coronary&#xD;
             intervention&#xD;
&#xD;
          -  Age ≤18 years&#xD;
&#xD;
          -  Known pregnancy, breast-feeding or intend to become pregnant during the study period&#xD;
&#xD;
          -  Contraindication for treatment with platelet inhibitors&#xD;
&#xD;
          -  Known allergy to glycoprotein IIb/IIIa inhibitors, aspirin, or heparin&#xD;
&#xD;
          -  Active peptic gastric or duodenal ulcer&#xD;
&#xD;
          -  History of major surgery (including intracranial or intraspinal) &lt;4 weeks&#xD;
&#xD;
          -  Active bleeding or bleeding diathesis&#xD;
&#xD;
          -  Stroke &lt;2 years (ischemic and hemorrhagic)&#xD;
&#xD;
          -  Known coagulation defect or relevant thrombocytopenia&#xD;
&#xD;
          -  Arteriovenous malformations or aneurysm&#xD;
&#xD;
          -  Severe liver insufficiency&#xD;
&#xD;
          -  Renal insufficiency requiring dialysis&#xD;
&#xD;
          -  Uncontrolled hypertension&#xD;
&#xD;
          -  Hypertensive retinopathy&#xD;
&#xD;
          -  Vasculitis&#xD;
&#xD;
          -  Fibrinolysis &lt;12 hours&#xD;
&#xD;
          -  Contraindication for cardiac magnetic resonance imaging at study entry&#xD;
&#xD;
          -  Patients without informed consent&#xD;
&#xD;
          -  Participation in another trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Luebeck</name>
      <address>
        <city>Luebeck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Holger Thiele</last_name>
      <email>holger.thiele@uksh.de</email>
    </contact>
    <investigator>
      <last_name>Holger Thiele</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>April 13, 2016</study_first_submitted>
  <study_first_submitted_qc>April 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2016</study_first_posted>
  <last_update_submitted>September 24, 2019</last_update_submitted>
  <last_update_submitted_qc>September 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Luebeck</investigator_affiliation>
    <investigator_full_name>Holger Thiele</investigator_full_name>
    <investigator_title>Director, Department of Cardiology/Angiology/Intensive Care Medicine, University Heart Center Luebeck</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>polysaccharide-K</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

